Pharmaceuticals
Suboxone Tooth Decay Litigation Update: Key Developments and What They Mean for Plaintiffs
The article discusses the latest developments in the Suboxone tooth decay litigation, highlighting procedural milestones and the implications for plaintiffs seeking justice against Indivior.
Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has published peer-reviewed data in the Journal of Dermatological Treatment, highlighting PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a new, non-immunosuppressive treatment approach.
Creative Biolabs Advances Single-Domain Antibody Solutions to Meet Therapeutic Demands
Creative Biolabs is enhancing the development of single-domain antibodies (sdAbs), offering innovative solutions for oncology, neurology, and infectious diseases, highlighting their potential to revolutionize treatment approaches.
Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Phlow Corp. Secures $37 Million in Series C Funding to Enhance U.S. Pharmaceutical Supply Chain
Phlow Corp.'s recent $37 million Series C funding round, led by Align Private Capital, underscores its commitment to addressing critical shortages in essential medicines and advancing U.S.-based pharmaceutical manufacturing.
Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
Soligenix Inc. is developing SGX945, a promising treatment for Behçet’s disease, addressing the critical need for more effective therapies for this rare condition.
Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology
Nutriband Inc. is pioneering in the development of abuse-deterrent transdermal patches, aiming to address critical public health needs with its AVERSA Fentanyl and Buprenorphine candidates.
SASMAR Pharma Strengthens Market Position with Acquisition of Goodwin Nutrition Srl and Moringa Boost Brand
SASMAR Pharmaceuticals' acquisition of Goodwin Nutrition Srl and its Moringa Boost brand signifies a strategic expansion in the health and wellness sector, aiming to meet growing consumer demand for high-quality nutritional supplements.
Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promise in reducing the condition's severity and duration in cancer patients.
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment
The European Medicines Agency grants Orphan Designation to Candel Therapeutics' CAN-2409, highlighting its potential to address the significant unmet medical need in pancreatic cancer treatment across Europe.
Akari Therapeutics CEO Unveils Novel ADC Platform Targeting Cancer Resistance
Akari Therapeutics, under CEO Abizer Gaslightwala, is pioneering a novel ADC platform aimed at overcoming cancer resistance and enhancing treatment durability through immune system activation.
GeoVax to Announce Q2 2025 Financial Results and Corporate Update
GeoVax Labs, Inc. is set to disclose its second quarter 2025 financial outcomes and a corporate update, highlighting its progress in vaccine and immunotherapy development for infectious diseases and cancer.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
CNS Pharmaceuticals Inc. CEO Highlights Company's Vision at Virtual Investor Conference
CNS Pharmaceuticals Inc. CEO John Climaco's participation in the Virtual Investor Summer Spotlight Conference underscores the company's commitment to developing innovative treatments for brain and central nervous system cancers.
NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.
Nutriband Inc. Announces Key Dates for 25% Preferred Stock Dividend
Nutriband Inc. (NASDAQ: NTRB) has set important dates for its 25% preferred stock dividend, linking the dividend's value to the FDA approval of its AVERSA Fentanyl product, marking a significant milestone for shareholders and the company's growth in the pharmaceutical sector.
Fifty 1 Labs and UAV Corp Announce Strategic Partnership to Acquire BioSpark AI for Drug Repurposing Advancements
Fifty 1 Labs, Inc. and UAV Corp have announced a strategic partnership and intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through AI and large language model technologies.
Oragenics Inc. Secures U.S. Manufacturing Partner for Concussion Drug Ahead of Phase IIb Trials
Oragenics Inc. has partnered with Sterling Pharma Solutions for the GMP production of its concussion drug candidate, ONP-002, marking a significant step towards Phase IIb trials and underscoring the importance of domestic manufacturing in clinical development.
NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference
Kairos Pharma Ltd. (NYSE American: KAPA) will present its advancements in cancer therapeutics at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its potential to address drug resistance in cancer treatments.
Soligenix Inc. Anticipates Key Catalysts in 2025 for Rare Disease Treatments
Soligenix Inc. is poised for significant advancements in its rare disease treatment pipeline, with key updates expected in 2025 that could impact its stock valuation and the medical community.
Branded Legacy Announces Leadership Overhaul and Strategic Merger to Enter Addiction Therapeutics Market
Branded Legacy (OTC: BLEG) undergoes a complete leadership transition and plans a merger with a company specializing in advanced intranasal drug delivery, aiming to make a significant impact in the addiction therapeutics space with projected first-year revenues of $40 million.
Nutriband Inc. Founder Shares Vision and Strategy on Smart Money Circle Podcast
Nutriband Inc.'s founder Serguei Melnik discusses the company's unique approach to biotech entrepreneurship and its revenue-generating products on the Smart Money Circle Show, highlighting its potential for long-term value.
ABVC BioPharma Achieves $150K Milestone in Licensing Strategy, Highlighting Growth in Botanical Therapeutics
ABVC BioPharma's recent $150,000 milestone payment from AiBtl BioPharma underscores the success of its licensing-first strategy and the growing interest in its CNS-focused botanical therapeutics.
Jupiter Neurosciences Advances in Treating Neuroinflammation and Aging with JOTROL™ and Nugevia™
Jupiter Neurosciences Inc. is making strides in treating central nervous system disorders and tapping into the longevity market with its innovative products JOTROL™ and Nugevia™, highlighting the potential to combat aging and neuroinflammation.
Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Potential $2 Billion Global Opportunity
Soligenix Inc. outlines significant clinical and strategic milestones for its rare disease therapies, including Phase 3 FLASH 2 results for HyBryte(TM) and updates on psoriasis and Behçet’s Disease treatments, projecting over $90 million in U.S. annual sales and global opportunities exceeding $2 billion.
Quantum BioPharma Submits MS Drug Candidate to UK's ILAP Program
Quantum BioPharma Ltd. advances its multiple sclerosis treatment, Lucid-MS, through the UK's Innovative Licensing and Access Pathway, aiming to accelerate patient access to this innovative therapy.
Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15
Silo Pharma Inc. is on the verge of receiving crucial preclinical study results for SPC-15, a potential breakthrough in PTSD treatment, marking a significant step towards addressing a long-unmet medical need.
Biotech Sector Rebounds with Innovative Therapies and Strategic Growth in 2025
The biotech sector is witnessing a significant rebound in 2025, driven by scientific advancements, clinical progress, and a favorable investment climate, highlighting four stocks with potential for growth.